SCHEMBL7669283

SCHEMBL7669283

CC(C)(C)OC(=O)CNS(=O)(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 2/20 0.58
GAA P10253 2/20 0.51
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 1/20 0.51
NPC1 O15118 1/20 0.51
HPGD P15428 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TSHR P16473 1/20 0.51
F2 P00734 3/20 0.47
TMPRSS6 Q8IU80 1/20 0.47
KMT2A Q03164 1/20 0.47
PRSS1 P07477 1/20 0.46
PRSS2 P07478 1/20 0.46
PRSS3 P35030 1/20 0.46
PKM P14618 1/20 0.45
MMP1 P03956 2/20 0.43
MMP12 P39900 1/20 0.43
PTPRC P08575 2/20 0.42
GFER P55789 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7667880 0.90 LMNA (0.54) MEP1BALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL7673504 0.87 ALDH1A1 (0.54) MEP1BGAAALDH1A1KDM4ENPC1
SCHEMBL28588397 0.87 ALDH1A1 (0.51) MEP1BGAAALDH1A1KDM4ENPC1
SCHEMBL7673440 0.86 MEP1B (0.60) MEP1BALDH1A1TSHRF2TMPRSS6
SCHEMBL19450297 0.84 MMP2 (0.56) MEP1BGAAALDH1A1KDM4ENPC1
SCHEMBL6799380 0.84 ALDH1A1 (0.56) MEP1BGAAALDH1A1KDM4ENPC1
SCHEMBL5090951 0.84 CA1 (0.57) GAAALDH1A1KDM4ENPC1HPGD
SCHEMBL7690859 0.84 MEP1B (0.62) MEP1BF2TMPRSS6KMT2APRSS1
SCHEMBL7675632 0.83 SMN1; SMN2 (0.51) MEP1BGAAALDH1A1KDM4ENPC1
SCHEMBL7663740 0.83 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2F2TMPRSS6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed